Eli Lilly recently reported that the commencement of its LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib (LOXO-292) for treatment-naïve RET fusion-positive Non-Small Cell Lung Cancer (NSCLC) patients conducted in up to 158 clinical investigator sites...